−Removed: Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
+Added: Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer
+Added: Purchases of Equity Securities.
Market Information
2 unchanged sentences
There is no established public trading market for our Class B common stock.
−Removed: As of March 22, 2021, we had 12 holders of record of our Class A common stock.
As of March 4, 2022, we had 1 holder of record of our Class B common stock.
+Added: As of March 4, 2022, we had approximately 204 holders of record of our Class A common stock.
+Added: This amount does not take into account shareholders whose shares are held in “street name” by brokerage houses or other intermediaries.
+Added: The closing price of our common stock on March 4, 2022 was $13.51.
We do not anticipate declaring or paying any cash dividends to holders of our Class A common stock in the foreseeable future.
10 unchanged sentences
Subsidiaries of BV LLC are generally subject to similar legal limitations on their ability to make distributions to BV LLC.
−Removed: Use of Proceeds
−Removed: On February 10, 2021, our Registration Statement on Form S-1 (File No.
−Removed: 333-252238) was declared effective by the SEC for our IPO pursuant to which we registered and sold an aggregate of 9,200,000 shares of our Class A common stock (including 1,200,000 shares sold pursuant to the underwriters' over-allotment option) at a price of $13.00 per share.
−Removed: Morgan Stanley & Co.
−Removed: Morgan Securities LLC and Goldman Sachs & Co.
−Removed: LLC acted as joint book-running managers in the offering.
−Removed: Canaccord Genuity Securities LLC acted as lead manager in the offering.
−Removed: The offering commenced on February 11, 2021 and did not terminate before all of the securities registered in the registration statement were sold.
−Removed: The offering closed on February 16, 2021, resulting in net proceeds of $111.2 million after deducting underwriters' discounts and commissions of $8.4 million.
−Removed: No payments were made by us to directors, officers, general partners or persons owning 10% or more of our common stock or to their associates, or to our affiliates.
−Removed: We used the net proceeds to us from the IPO to purchase 9,200,000 newly-issued LLC Interests from BV LLC at a purchase price per interest equal to the IPO price per share of Class A common stock.
−Removed: As sole managing member of BV LLC, we caused BV LLC to use the proceeds it received as follows:
−Removed: (i) to pay fees and expenses of approximately $3.8 million in connection with the IPO and the Transactions (ii) to satisfy the $3.3 million cash entitlement of the Continuing LLC Owner in respect of the EPR Unit held by the Continuing LLC Owner, (iii) to pursue future potential acquisition opportunities and (iv) for general corporate purposes.
−Removed: There has been no material change in the use of proceeds as described in the final prospectus filed on February 12, 2021.
−Removed: Table o f contents
+Added: Performance Graph
+Added: The following performance graph is not deemed to be “soliciting material” or to be “filed” with the SEC or subject to Regulation 14A or 14C or to the liabilities of Section 18 of the Exchange Act.
+Added: This information will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except to the extent we specifically incorporate this information by reference.
+Added: The following performance graph compares the cumulative 11 months cumulative total return to stockholders on our Class A common stock relative to the cumulative total returns on the Nasdaq Composite Index and the S&P 500 Health Care Equipment Index for the period commencing on February 11, 2021 (the date our Class A common stock commenced trading on Nasdaq) through December 31, 2021 assuming an initial investment of $100.
+Added: Nasdaq Composite Index and S&P 500 Health Care Equipment Index will not be deemed incorporate by reference into any other filings under the Exchange Act or the Securities Act of 1933, as amended, except to the extent we specifically incorporate.
+Added: Note that historic stock price performance is not necessarily indicative of future stock price performance.
+Added: Table of Co n tents
+Added: 2/11/21 3/31/21 6/30/21 9/30/21 12/31/21
+Added: Bioventus Inc.
+Added: $ 100.00 $ 79.54 $ 91.62 $ 73.71 $ 75.43
+Added: NASDAQ Composite $ 100.00 $ 94.54 $ 103.69 $ 103.46 $ 112.20
+Added: S&P 500 Health Care Equipment $ 100.00 $ 96.41 $ 104.95 $ 110.16 $ 113.99
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.